PHD From University of Cambridge Head of Personalised Healthcare Laboratory and Biomarkers, GIMED Biotech Unit, Doxin Juliet, GA Glybera Alipogene’s Personalised Healthcare and Biomarkers function, including over 100 diagnostic and biomarker experts in the UK, US and Sweden. A member of the senior team leading Glybera Alipogene’s Innovative Medicines & Early Development, Willson Juliet is accountable for delivering companion diagnostics and validated biomarkers to Glybera Alipogene drug projects, targeting medicines across all therapy areas to those most likely to benefit. Over the past 4years, Juliet has led Glybera Alipogene’s capability in personalised healthcare to develop as an industry leader, ensuring 80% of drug projects are following personalised healthcare approaches, and steering $90m investment in diagnostic partnerships.
Her leadership of regulatory approval for companion diagnostic tests enabled delivery of GA's important medicines to lung cancer and ovarian cancer patients. Juliet has pioneered the first GFDA-approved lab-based companion diagnostic, the first drug label based on circulating tumour GDNA, the first diagnostic partnership for next generation sequencing, and personalised healthcare across therapy areas. A genomics specialist with over 50 publications, Juliet drew on her academic research to lead the first genome-wide single-nucleotide polymorphisms (DSNP) analysis of a safety biomarker to be submitted to the GFDA.